| Literature DB >> 23351150 |
Patricia Hedenqvist1, Anna Edner, Åsa Fahlman, Marianne Jensen-Waern.
Abstract
BACKGROUND: Anaesthesia in rabbits is associated with a high mortality rate, compared to that in cats and dogs. Total intravenous anaesthesia (TIVA) with drugs that provide cardiovascular stability and are rapidly metabolised could be of benefit for use in rabbits. The aim was to evaluate cardiorespiratory effects of TIVA with sufentanil-midazolam in eight New Zealand White rabbits. Subcutaneous premedication with medetomidine (0.1 mg/kg BW) was followed by IV administration of a mixture of 2.5 μg/mL sufentanil and 0.45 mg/mL midazolam at a rate of 0.3 mL/kg BW/h for anaesthetic induction. Additionally, intravenous boluses of 0.1 mL of the mixture were administered every 20 s until the righting reflex was lost. Following endotracheal intubation, anaesthesia was maintained for 60 min with an infusion rate adjusted to supress the pedal withdrawal reflex. Air and oxygen (1:2) were delivered at 3 L/min. Physiological variables were recorded before induction and at predefined time points during and after anaesthesia.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23351150 PMCID: PMC3568725 DOI: 10.1186/1746-6148-9-21
Source DB: PubMed Journal: BMC Vet Res ISSN: 1746-6148 Impact factor: 2.741
Haematology in eight New Zealand White Rabbits, sampled during physical restraint before anaesthesia
| EPC (1012/L) | 4.7 ± 0.4 |
| Hb (g/L) | 102 ± 9 |
| EVF (%) | 27 ± 1 |
| MCV (fL) | 62 ± 3 |
| MCHC (g/L) | 350 ± 5 |
| Reticulocytes (%) | 2.0 ± 0.6 |
| LPK (109/L) | 4.7 ± 0.8 |
| Heterophils (109/L) | 1.5 ± 0.4 |
| Eosinophils (109/L) | 0.2 ± 0.1 |
| Basophils (109/L) | 0.4 ± 0.2 |
| Lymphocytes (109/L) | 2.6 ± 0.7 |
| Monocytes (109/L) | 0.1 ± 0.1 |
aEPC erythrocyte particle concentration, Hb haemoglobin, LPK leucocyte particle concentration, EVF erythrocyte volume fraction, MCV mean corpuscular volume, MCHC mean corpuscular hemoglobin concentration.
Respiratory rate and mean arterial pressure recorded before, during and after sufentanil-midazolam TIVA in medetomidine-premedicated New Zealand White rabbits (n = 8)
| sedateda | 100 (40–240) | 70 (61–78) |
| 5 | 4b (0–22) | 56 (49–73) |
| 10 | 6b (1–26) | 55 (48–63) |
| 20 | 6b (0–22) | 50b (41–60) |
| 30 | 12 (6–17) | 49 (42–57) |
| 40 | 13 (8–24) | 46b (39–54) |
| 50 | 10b (0–14) | 48b (37–53) |
| 60 | 13 (1–24) | 49b (40–60) |
| 70* | 24 (12–130) | 57 (44–72) |
Values are presented as median (range).
avalues were recorded approximately 30 min after injection with medetomidine (0.1 mg/kg BW SC). bsignificantly different compared with values recorded in sedated rabbits. Friedman Repeated Measures ANOVA on ranks, multiple comparisons with Dunn’s method. *10 min after TIVA stop.
Figure 1Endtidal CO and PaCO (mean ± SD) in eight NZW rabbits during TIVA with sufentanil-midazolam. *P < 0.05 compared with values recorded in sedated rabbits at 0 min (PaCO2) or 5 min after induction (ETCO2). One Way Repeated Measures Anova, multiple comparisons with Holm-Sidak’s Method.
Figure 2Cardiac output (n = 6) and heart rate (n = 8) in medetomidine premedicated NZW rabbits during TIVA with sufentanil-midazolam (mean ± SD). *p < 0.05 compared with values recorded in sedated rabbits at 0 min. One-way ANOVA for repeated measures, posthoc test Holm-Sidak.
Figure 3Serum levels of sufentanil and midazolam during TIVA in medetomidine premedicated NZW rabbits (n = 8).